Vera Therapeutics Eyes $1.5–$2.5B Peak Atacicept Sales After Phase 3 Success
Vera submitted a Biologics License Application for atacicept after Phase 3 data in the New England Journal of Medicine and at Kidney Week showed safety and efficacy. The company targets 15–25% of a $10 billion U.S. IgA nephropathy market at launch in 2026, supporting $1.5–$2.5 billion peak sales.
1. Clinical Data and FDA Filing
Atacicept’s recent Phase 3 trial demonstrated a statistically significant reduction in pathogenic IgA accumulation and was well tolerated, as published in the New England Journal of Medicine and presented at Kidney Week. Following these results, Vera submitted a Biologics License Application under the FDA’s Accelerated Approval pathway, targeting mid-2026 commercialization.
2. Market Opportunity
IgA nephropathy affects roughly 100,000 patients in the U.S., half of whom require advanced therapies. Vera projects a $10 billion U.S. addressable market and aims to capture 15–25% share, underpinning $1.5–$2.5 billion in peak annual sales.
3. Valuation and Competitive Outlook
Despite the de-risked profile, the stock has remained flat ahead of competitor regulatory events; Vera trades at about 5× projected peak revenues. The company’s late-stage asset, pipeline optionality and potential acquisition appeal suggest significant upside if atacicept reaches blockbuster status.